Publications by authors named "Reiko Nagai"
Background: In this open-label, Phase 1 study, we explore the safety and efficacy of E7389-LF (liposomal formulation of eribulin) in Japanese patients with advanced solid tumors.
Methods: This open-label, Phase 1 study enrolled Japanese adult patients to receive E7389-LF for the treatment of advanced solid tumors. Treatment with E7389-LF 2.
Article Synopsis
- A phase 1 study was expanded to evaluate the safety and effectiveness of a liposomal formulation of eribulin, E7389-LF, in patients with metastatic breast cancer that lacks the HER2 protein.
- Patients received E7389-LF every three weeks, with tumor evaluations and adverse events closely monitored, showing significant treatment-related side effects like neutropenia.
- The study found that 35.7% of patients responded to treatment, with a median progression-free survival of 5.7 months and an overall survival of 18.3 months, highlighting the need for prophylactic measures in patients at risk for severe side effects.
Purpose: We report the dose-escalation part of a phase I study of liposomal eribulin (E7389-LF) in Japanese patients with advanced solid tumors and no alternative standard therapy.
Patients And Methods: Patients ≥20 years old were enrolled. E7389-LF doses of 1.
Article Synopsis
- Daprodustat, a medication that inhibits a specific enzyme, was tested for its effectiveness in treating anemia in Japanese patients undergoing peritoneal dialysis over a year-long study.
- The study involved 56 participants who started with an average hemoglobin level of 10.9 g/dL, which increased to the target range of 11.0-13.0 g/dL by week 12 and was maintained throughout the study.
- Common side effects included nasopharyngitis and infections, but overall, daprodustat was well tolerated, with no reported deaths during the study.
Article Synopsis
- Daprodustat is an oral medication designed to stimulate red blood cell production by preventing the breakdown of a protein that helps respond to low oxygen levels; its safety and effectiveness were evaluated in a year-long study involving Japanese patients with anemia due to chronic kidney disease (CKD).
- The study involved 299 patients who were not on dialysis and compared daprodustat with another treatment, CERA, with adjustments made to dosages based on patients' hemoglobin levels.
- Results showed that the mean hemoglobin levels after the 40-52 week period were similar for both treatments, with daprodustat at 12.0 g/dL and CERA at 11.9 g/dL, and both treatments
In mesophyll cells of the aquatic monocot , red light induces rotational cytoplasmic streaming, which is regulated by the cytoplasmic concentration of Ca. Our previous investigations revealed that red light induces Ca efflux across the plasma membrane (PM), and that both the red light-induced cytoplasmic streaming and the Ca efflux are sensitive to vanadate, an inhibitor of P-type ATPases. In this study, pharmacological experiments suggested the involvement of PM H-ATPase, one of the P-type ATPases, in the photoinduction of cytoplasmic streaming.
View Article and Find Full Text PDFStudy Objective: To identify whether baseline demographic factors or subjective sleep variables are associated with the outcomes following treatment with eszopiclone using data from a recent randomized controlled trial of 78 Japanese subjects with insomnia who were treated with 2 mg eszopiclone per day.
Methods: We performed a post hoc analysis of factors including sleep latency (SL), wake time after sleep onset (WASO) (both assessed via sleep diaries), and several demographic variables. Subjects with a SL or WASO > 30 min at baseline and with evaluable SL/WASO data at Week 4 were included in SL and WASO remitter analyses, respectively; those with a SL or WASO ≤ 30 min at Week 4 were defined as SL or WASO remitters, respectively.
Introduction: The long-term efficacy and safety of donepezil 10 mg in patients with dementia with Lewy bodies (DLB) were investigated in a 52-week Phase 3 trial.
Methods: This 52-week study consisted of 16-week randomized placebo-controlled (RCT) and 36-week open-label extension phases. Of 142 DLB patients enrolled in the RCT phase (three arms: placebo, 5 mg, and 10 mg), 110 entered the extension phase.
Two blazeispirane derivatives including blazeispirols G and I were isolated from the cultured mycelia of the fungus Agaricus blazei Murill and were established to be (20S, 22S, 23R, 24S)-14 beta,22: 22,25-diepoxy-5-methoxy-des-A-ergosta-5,7,9-triene-11 alpha,23-diol and (20S, 22S, 23R, 24S)-14 beta,22:22,25-diepoxy-5-methoxy-des-A-ergosta-5,7,9,11-tetraene-23,28-diol by comparison of extensive 1D and 2D NMR spectral data with that of blazeispirol A. Furthermore, four blazeispirol derivatives blazeispirols, U, V, V(1) and Z(1) were isolated form the same source described above. Their structures were determined to be (20S, 22S, 23R, 24S)-14 beta,22:22,25-diepoxy-23-hydroxyergosta-4,6,8,11-tetraen-3-one, (20S, 22S, 23R, 24S)-14 beta,22:22,25-diepoxy-6 alpha,7 alpha,23-trihydroxyergosta-4,8,11-trien-3-one, (20S, 22S, 23R, 24S)-14 beta,22:22,25-diepoxy-6 beta,7 alpha,23-trihydroxyergosta-4,8,11-trien-3-one and (20S, 22S, 23R, 24S)-14 beta,22:22,25-diepoxy-23-hydroxy-4,5-seco-ergosta-6,8-diene-3,5-dione by extensive 1 D and 2D NMR spectral data.
View Article and Find Full Text PDF